Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca    AZN   GB0009895292

ASTRAZENECA (AZN)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

AstraZeneca Buys Back 318283 Shares

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/30/2012 | 12:23pm CET

AstraZeneca PLC (>> AstraZeneca plc) said Monday it has purchased 318,283 ordinary shares on April 27 at a price of 2666 pence per share for cancellation.

-Shares at 1005 GMT up 1%, at 2704 pence, valuing the company at GBP34 billion.

-By Mark Shapland, Dow Jones Newswires; +44 207 8429358; [email protected]

Stocks mentioned in the article : AstraZeneca plc
Valeurs citées dans l'article
ChangeLast1st jan.
ASTRAZENECA -0.67% 546 Delayed Quote.-3.36%
ASTRAZENECA -1.04% 4725 Delayed Quote.-6.82%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ASTRAZENECA
02/22ASTRAZENECA : FluMist back on CDC's recommended list of flu vaccines
AQ
02/22ASTRAZENECA : FDA Approves AstraZenecas Lung Cancer Treatment after Rejecting Me..
AQ
02/22ASTRAZENECA : AZ adds another Ionis drug in $330m kidney disease deal
AQ
02/21ASTRAZENECA : It's OK to use nasal spray flu vaccine again, US panel says
AQ
02/21ASTRAZENECA : U.S. health officials reverse stance on AstraZeneca's flu vaccine
RE
02/21ASTRAZENECA : Announces Renewed Recommendation and Availability of FLUMIST QUADR..
BU
02/21ASTRAZENECA : US panel says it's OK to use nasal spray flu vaccine again
AQ
02/20MERCK AND : Groundbreaking lung cancer approval a big boost for AZs Imfinzi
AQ
02/19ASTRAZENECA : European indices gain tracking Asian equities
AQ
02/19MERCK AND : - Selumetinib Granted Orphan Drug Designation by the U.S. FDA for Ne..
AQ
More news
News from SeekingAlpha
02/223 THINGS IN BIOTECH YOU SHOULD LEARN : February 21, 2018 
02/21CDC on board with AstraZeneca's Quadrivalent flu vaccine for next year 
02/21YOUR DAILY PHARMA SCOOP : Portola Update, Wave Life Sciences To Collaborate With.. 
02/20Ionis out-licenses kidney disease candidate to AstraZeneca for up to $330M 
02/19AstraZeneca Scores FDA First, Time To Capitalize Before Competitors Roll In 
Financials ($)
Sales 2018 22 345 M
EBIT 2018 5 638 M
Net income 2018 2 132 M
Debt 2018 14 076 M
Yield 2018 4,12%
P/E ratio 2018 33,54
P/E ratio 2019 26,48
EV / Sales 2018 4,44x
EV / Sales 2019 4,18x
Capitalization 85 057 M
Chart ASTRAZENECA
Duration : Period :
AstraZeneca Technical Analysis Chart | AZN | GB0009895292 | 4-Traders
Technical analysis trends ASTRAZENECA
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 33
Average target price 72,8 $
Spread / Average Target 8,9%
EPS Revisions
Managers
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Dunoyer Chief Financial Officer & Executive Director
Sean Bohen Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA-6.82%85 057
JOHNSON & JOHNSON-6.33%349 006
NOVARTIS-2.67%224 221
PFIZER-0.58%213 155
ROCHE HOLDING LTD.-9.33%206 183
MERCK AND COMPANY-2.29%148 618